vimarsana.com

Page 46 - அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting

Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting News provided by Share this article Share this article SUZHOU, China, April 15, 2021 /PRNewswire/ Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functional anti-PD-L1 and TGF-β trap fusion protein, in a poster during the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from April 10 th to 15 Abstract Number: 972 About TST005 TST005, is a bi-functional anti-PD-L1 and TGF-β trap fusion protein designed to simultaneously target two immuno-suppressive pathways, transforming growth factor β-(TGF-β) and programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system. TST005 consists of a high affinity PD-

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.